

## Invitation to presentation of Isofol´s report for the first quarter of 2023

**GOTHENBURG, Sweden, April 25, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for the first quarter of 2023 on Wednesday, May 3, 2023. On the same day, Isofol invites investors, analysts, and media to an audiocast. The company’s chairman and CEO gives an update with a subsequent question and answer session.**

In conjunction with the publication of the interim report for the first quarter of 2023, Isofol invites investors, analysts, and media to an audiocast on May 3, 2023 at 11:00 a.m. CEST. The presentation will be held by Isofol’s Chairman of the board, Mats Franzén and CEO Thomas Andersson, who will give an update on the first quarter, followed by a Q&A-session. The presentation will be held in Swedish.

### **Date and time**

May 3, 2023, at 11:00 a.m. CEST

### **Link to audiocast**

If you wish to participate via the web and ask written questions, please use the link below:

<https://ir.financialhearings.com/isofol-medical-q1-2023>

The presentation will also be available on Isofol’s website after the broadcast:

<https://isofolmedical.com/company-presentations/>

### **For further information, please contact**

#### **Isofol Medical AB (publ)**

Mats Franzén, Chairman of the Board

E-mail: [mats@efficere.se](mailto:mats@efficere.se)

Phone: +46 (0) 704-47 29 09

Thomas Andersson, CEO

E-mail: [thomas.andersson@isofolmedical.com](mailto:thomas.andersson@isofolmedical.com)

Phone: +46 (0)709-44 00 93

*The information was submitted for publication, through the agency of the contact person set out above, at 16:40 CEST on April 25, 2023.*

### **About Isofol Medical AB (publ)**

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

[www.isofolmedical.com](http://www.isofolmedical.com)